- Home
- SLN vs XCBE Comparison
SLN vs XCBE Comparison
Compare SLN & XCBE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLN | XCBE |
|---|---|---|
| Founded | 1994 | 2025 |
| Country | United Kingdom | United States |
| Employees | 116 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.2M | 278.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLN | XCBE |
|---|---|---|
| Price | $7.13 | $9.91 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $42.60 | N/A |
| AVG Volume (30 Days) | ★ 303.7K | 69.3K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.19 | $9.75 |
| 52 Week High | $8.40 | $9.91 |
Technical Indicators
Market Signals| Indicator | SLN | XCBE |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 63.95 |
| Support Level | $5.91 | $9.75 |
| Resistance Level | $7.21 | N/A |
| Average True Range (ATR) | 0.47 | 0.01 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 34.77 | 100.00 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About XCBE X3 Acquisition Corp. Ltd. Class A Ordinary Shares
X3 Acquisition Corp Ltd is a blank check company.